Taytulla Birth Control Pill Recall Issued Over Pregnancy Risk

Women given sample packs of the birth control pill Taytulla may face an increased risks of unintended pregnancy, due to a manufacturing defect that caused the pills to be packaged out of order. 

The FDA announced a Taytulla recall on May 29, warning that some placebo capsules were placed in the incorrect spot in sample packs, causing the birth control pills to fail to protect against pregnancy.

Taytulla (norethindrone acetate and ethinyl estriadol) is an oral contraceptive manufactured by Allergan. The company indicates that it received a physical report of the pills being packaged out of sequence in some sample packs.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

In some Taytulla sample packs, the first four days of the birth control pills were non-hormonal placebo pills, instead of active capsules, which means that the first four days a woman uses the month-long regimen, she is not actually protected against unintended pregnancy. Additionally, Allergan noted that since the problem occurred in sample packs, the reversed order of the pills may not be immediately apparent, since they are typically given to new users.

The recall affects Taytulla Softgel Capsules 1mg/20 mcg 6×28 Sample packs. They are 28-count blister cards with 24 pink softgel capsules with “WC” printed on the outer shell in white. These are the active capsules. There are also four maroon softgel capsules, also printed with “WC” which are the placebo pills. The recalled packs have a lot number of 5620706 and an expiration date of May 2019. They have been on the market since August 27, 2017. The pills were distributed to healthcare providers nationwide.

The company has issued recall letters to all of its customers, asking for a return of all the recalled sample packs from lot #5620706 with a May 2019 expiration date.

Consumers with questions can contact Allergan by calling 800-678-1605. Consumers or health care providers who have experienced adverse events or quality problems with the recalled birth control pill are encouraged to file a report with the FDA’s MedWatch Adverse Event Reporting Program.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Lawsuit Indicates Tepezza Hearing Impairment Warnings Were Delayed By Horizon Therapeutics, Disregarding Safety of Users
Lawsuit Indicates Tepezza Hearing Impairment Warnings Were Delayed By Horizon Therapeutics, Disregarding Safety of Users (Posted today)

New Jersey man indicates he has been left with permanent hearing impairment from Tepezza, alleging that Horizon Therapeutics failed to instruct doctors about the importance of conducting hearing tests on patients using the thyroid eye disease drug.

LINX Device Lawsuit Alleges GERD Implant Broke and Failed Due to Manufacturing Defects
LINX Device Lawsuit Alleges GERD Implant Broke and Failed Due to Manufacturing Defects (Posted 4 days ago)

A Minnesota man has filed a LINX reflux lawsuit against Ethicon and Torax Medical, after a LINX device meant to help treat GERD, broke inside of him, requiring surgical removal.